Discharge of the EMA Budget for 2022

by name voted on 11.04.2024

Summary

The European Parliament grants discharge to the Executive Director of the European Medicines Agency regarding its 2022 budget implementation. It notes achievements in medicine regulation but highlights concerns over long-term lease liabilities in London.

9 11.04.2024

Report

budget

health

pharmacy

public administration

public finance and budget policy

Key points

In force from 01/01/2022 Out of force from 31/12/2022

The European Parliament grants discharge to the Executive Director of the EMA for the successful implementation of its 2022 budget.
The agency is primarily funded by fees from the pharmaceutical industry, which account for approximately 88% of its revenue.
There is a major financial concern regarding the agency's former office in London, with potential outstanding costs reaching 366 million euros by 2039.
The report highlights a need for better gender and geographical balance within the agency's senior management levels.

Vote

PPE

S&D

Renew

PfE

Verts/ALE

ECR

The Left

NI

ESN

Total

Speeches

31 Speeches in total

Pro

Contra

Ernő SCHALLER-BAROSS

Ernő SCHALLER-BAROSS

NI

1:07 min

26. Discharge 2022 (debate)

Gilles LEBRETON

Gilles LEBRETON

ID

1:25 min

26. Discharge 2022 (debate)

Documents (PDFs)

DRAFT OPINION on discharge in respect of the implementation of the general budget of the European Medicines Agency for the financial year 2022 OPINION on discharge in respect of the implementation of the general budget of the European Medicines Agency for the financial year 2022 DRAFT REPORT on discharge in respect of the implementation of the budget of the European Medicines Agency for the financial year 2022 REPORT on discharge in respect of the implementation of the budget of the European Medicines Agency for the financial year 2022 Discharge 2022: European Medicines Agency

These raw data are provided by the Open Data Portal of the European Union (data.europa.eu) and are licensed under ODC-BY 1.0.